Prestige Consumer Healthcare Inc. (PBH)
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
$45.60+0.75%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $2.2B
- P/E (trailing)
- 12.8
- Forward P/E
- 9.0
- 52-week range
- $42.62 – $71.07
- 52-week change
- −28.37%
- EPS (trailing)
- $3.57
- Analyst rating
- 1.7 Buy
- Next earnings
- Nov 5, 2026
Fiscal year to Mar 2026
- Revenue
- $1.1B (−4.32%)
- Net income
- $190M
- Operating margin
- 28.4%
- Diluted EPS
- $3.91
- Free cash flow
- $246M
From the company’s annual report on SEC EDGAR.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name.
Headquarters: Tarrytown, United States · 890 employees · prestigebrands.com